Mindray Reports Q3 2024 Financials: International Revenues Surge Over 18% Amid Domestic Challenges
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760) reported its Q3 2024 financial results, revealing...
BeiGene CCO Yin Min Detained Amid Investigation; Company Affirms Compliance Standards
On October 25, Yin Min, Chief Commercial Officer of BeiGene (NASDAQ: BGNE) Greater China, was...
Biogen Partners with Neomorph to Develop Molecular Glue Degraders for Alzheimer’s and Rare Diseases
U.S.-based Biogen Inc. (NASDAQ: BIIB) has announced a research collaboration with Neomorph to jointly develop...
Yantai Dongcheng Pharma Secures FDA Fast-Track Designation for 177Lu-LNC1004 in Thyroid Cancer
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that it has received...
Sunshine Guojian Pharmaceutical Secures NMPA Approval for Clinical Trials of SSGJ-626 in Lupus Indications
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA: 688336) has announced that it has received...
Zai Lab Reports Positive Phase III Results for KarXT, Showcasing Efficacy in Psychiatric Conditions
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced encouraging topline results from...
Sun-Novo Pharmaceuticals Gets Green Light for CAR-T Therapy Clinical Trial in Lupus Treatment
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) has secured approval from China’s National Medical...
GSK Secures Global Rights to Chimagen Biosciences’ T Cell-Engager in $850 Million Deal
UK pharmaceutical company GSK plc (NYSE: GSK) has entered into a licensing agreement with Chimagen...
Fosun Pharmaceutical Reports Q3 2024 Revenue Growth and R&D Progress
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its financial report...
Shanghai Pharmaceuticals Reports Q3 2024 Revenue Growth, Strengthens Drug Pipeline
China’s Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced its financial results for the...
Innovent Biologics’ Picankibart Shows 64.6% Skin Clearance in Phase II Psoriasis Study
China-based Innovent Biologics, Inc. (HKG: 1801) has announced encouraging results from the multi-center, open Phase...
Livzon Pharmaceutical’s Leuprorelin Acetate Microspheres Passes China’s GQCE
China’s Livzon Pharmaceutical Group Inc., (HKG: 1513, SHE: 000513) has announced that its leuprorelin acetate...
Xi’an Xintong Pharma’s Pradefavir Wins NMPA Nod for Chronic Hepatitis B Treatment
The National Medical Products Administration (NMPA) has granted market approval for pradefavir, a Category 1...
Eli Lilly’s Mounjaro Approved in Hong Kong for Obesity and Type 2 Diabetes Treatment
Eli Lilly & Co. (NYSE: LLY) has received market approval from Hong Kong’s Department of...
Clover Biopharmaceuticals Reports Strong Phase I Results for RSV Vaccine SCB-1019
China-based Clover Biopharmaceuticals Ltd. (HKG: 2197) has announced encouraging additional immunogenicity and safety data from...
Merck and Moderna Launch Phase III Study for Individualized Neoantigen Therapy in Lung Cancer
US pharmaceutical companies Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) and Moderna Inc. (NASDAQ:...
Merck’s Keytruda Gains Two Additional EU Indications for Gynecologic Cancer Treatment
Merck, Sharp & Dohme Inc., known as MSD (NYSE: MRK), has received two additional indication...
WuXi AppTec Reports Q3 2024 Revenues of RMB 10.46 Billion Amid Biosecure Act Challenges
WuXi AppTec Co., Ltd (SHA: 603259), the China-based Contract Development and Manufacturing Organization (CDMO) facing...
Monte Rosa Therapeutics Strikes Licensing Deal with Novartis for VAV1 Degraders
US-based Monte Rosa Therapeutics (NASDAQ: GLUE) has entered into a licensing agreement with Swiss pharmaceutical...
Jiangsu Hengrui Pharmaceuticals Advances Clinical Trials for Cancer Therapies with NMPA Clearance
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received clinical clearance from China’s National Medical...